The role of lithium in neurodegenerative diseases: New registries for old actors;El papel del litio en las enfermedades neurodegenerativas: Nuevos registros para viejos actores

Neurologia

Volumn 24, Issue 3, 2009, Pages 143-146

  Pérez Martínez, David A ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Alzheimer's disease; Amyotrophic Lateral Sclerosis; Glycogen synthase kinase 3 (GSK 3); Lithium; Neurodegenerative; Neuroprotector

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LITHIUM; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIPOLAR DISORDER; CHRONIC PATIENT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; REGISTER; REVIEW; SPINOCEREBELLAR DEGENERATION;

ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; TAU PROTEINS;

EID: 65749109482     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potencial therapeutics against acute brain injures and chronic neurodegerative diseases. J Pharmacol Sci 2005;99:307-321 (Pubitemid 41813422)
2. Cade JF. John Frederick Joseph Cade: family memories on the occasion of the 50th anniversary of his discovery of the use of lithium in mania 1949. Aust N Z J Psychiatry 1999;33:615-618
3. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Evid Based Ment Health 2004;7:72.
4. May A, Leone M, Afra J, Linde M, Sándor PS, Evers S, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006;13:1066-1077 (Pubitemid 44434311)
5. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93:8455-8459 (Pubitemid 26269579)
6. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, et al. The role of GSK-3 in synaptic plasticity. Br J Pharmacol 2008;153(Suppl. 1):S428-37.
7. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, et al. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 2008;7(Suppl. 1):57-66.
8. Patel DS, Dessalew N, Iqbal P, Bharatam PV. Structure-based approaches in the design of GSK-3 selective inhibitors. Curr Protein Pept Sci 2007;8:352-364 (Pubitemid 47317041)
9. Aghdam SY, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res 2007;4:21-31. (Pubitemid 46293881)
10. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006;7:1421-1434
11. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3: an overview of an over-achieving protein kinase. Curr Drug Targets 2006;7:1377-1388
12. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases and therapeutics. Neurochem Res 2007;32:577-595 (Pubitemid 46481289)
13. Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun 2002;295:102-106 (Pubitemid 34743782)
14. Ren M, Senatorov VV, Chen RW, Chuang DM. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 2003;100:6210-6215 (Pubitemid 36576955)
15. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007;33:43-55. (Pubitemid 46090309)
16. Pérez M, Hernández F, Lim F, Díaz-Nido J, Ávila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003;5:301-308 (Pubitemid 37411777)
17. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102:6990-6995 (Pubitemid 40675429)
18. Engel T, Hernández F, Ávila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006;26:5083-5090 (Pubitemid 44315289)
19. Engel T, Goñi-Oliver P, Lucas JJ, Ávila J, Hernández F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006; 99:1445-1455
20. Engel T, Goñi-Oliver P, Gómez de Barreda E, Lucas JJ, Hernández F, Ávila J. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis 2008;5:247-249
21. Engel T, Lucas JJ, Hernández F, Ávila J. A mouse model to study tau pathology related with tau phosphorylation and assembly. J Neurol Sci 2007;257:250-254 (Pubitemid 46856490)
22. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007;170:1669-1675 (Pubitemid 47339311)
23. Zhu X, Ávila J, Perry G, Smith MA. Treating the lesions, not the disease. Am J Pathol 2007;170:1457-1459 (Pubitemid 47339292)
24. Yoshiike Y, Tanemura K, Murayama O, Akagi T, Murayama M, Sato S, Sun X, Tanaka N, Takashima A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J Biol Chem 2001;276:32293-32299 (Pubitemid 37384895)
25. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 2002;321:61-64 (Pubitemid 34185499)
26. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423:435-439 (Pubitemid 36626994)
27. De Ferrari GV, Chacón MA, Barría MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Álvarez A, Bronfman M, Inestrosa NC. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 2003;8:195-208. (Pubitemid 36315228)
28. Inestrosa N, De Ferrari GV, Garrido JL, Álvarez A, Olivares GH, Barría MI, Bronfman M, Chacón MA. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem Int 2002;41:341-344
29. Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 2007;4:e182.
30. Shin JH, Cho SI, Lim HR, Lee JK, Lee YA, Noh JS, et al. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 2007;71:965-975
31. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008;155:567-572
32. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 2004;9:371-385 (Pubitemid 38534698)
33. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 2003;61:375-383 (Pubitemid 36945468)
34. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-136
35. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001;106:603-612
36. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 2008;17:170-178
37. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006;8:65-74.
38. Beyer JL, Taylor WD, MacFall JR, Kuchibhatla M, Payne ME, Provenzale JM et al. Cortical white matter microstructural abnormalities in bipolar disorder. Neuropsychopharmacology 2005;30:2225-2229
39. Nugent AC, Milham MP, Bain EE, Mah L, Cannon DM, Marrett S, et al. Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage 2006;30:485-497
40. Frazier JA, Breeze JL, Makris N, Giuliano AS, Herbert MR, Seidman L, et al. Cortical gray matter differences identified by structural magnetic resonance imaging in pediatric bipolar disorder. Bipolar Disord 2005;7:555-569
41. Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti M, et al. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology 2008;33:1229-1238
42. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007;62:7-16.
43. Regenold WT. Lithium and increased cortical gray matter-more tissue or more water? Biol Psychiatry 2008;63:e17.
44. Fornai F, Siciliano G, Manca ML, Murri L, Paparelli A, Ruggieri S. Lithium in ALS: from the bench to the bedside. Amyotroph Lateral Scler 2008;9:123-124
45. Meininger V, Shefner J, Cudkowicz M. Lithium therapy in ALS. Amyotroph Lateral Scler 2008;9:122.
46. Bedlack RS, Maragakis N, Heiman-Patterson T. Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. Proc Natl Acad Sci USA 2008;105:E17.
47. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-2057
48. Vanacore N, Galeotti F. A clinical specification for a randomized clinical trial on lithium in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:E35.
49. Ensayo clínico registrado NCT00703677 en ClinicalTrials.org. URL: http://clinicaltrials.gov/ct2/show/NCT00703677 [acceso 15.09.2008].
50. Ensayo clínico registrado NCT00683943 en ClinicalTrials.org. URL: http://clinicaltrials.gov/ct2/show/ NCT00683943 [acceso 15.09.2008].
51. Ensayo clínico registrado NCT00750061 en ClinicalTrials.org. URL: http://clinicaltrials.gov/ct2/show/NCT00750061 [acceso 15.09.2008].
52. MacAulay K, Woodgett JR. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes. Expert Opin Ther Targets 2008;12:1265-1274
53. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 2006;7:1435-1441
54. Martínez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer and inflammation. Med Res Rev 2002;22:373-384 (Pubitemid 34620473)
55. Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 2008;11:533-543